Literature DB >> 26838693

Atrial fibrillation and risk of stroke: a nationwide cohort study.

Christine Benn Christiansen1, Thomas A Gerds2, Jonas Bjerring Olesen3, Søren Lund Kristensen3, Morten Lamberts3, Gregory Y H Lip4, Gunnar H Gislason2,5,6, Lars Køber7, Christian Torp-Pedersen8.   

Abstract

AIM: Although the relation between stroke risk factors and stroke in patients with atrial fibrillation (AF) has been extensively examined, only few studies have explored the association of AF and the risk of ischaemic stroke/systemic thromboembolism/transient ischaemic attack (stroke/TE/TIA) in the presence of concomitant stroke risk factors. METHODS AND
RESULTS: From nationwide registries, all persons who turned 50, 60, 70, or 80 from 1997 to 2011 were identified. Persons receiving warfarin were excluded. The absolute risk of stroke/TE/TIA was reported for a 5-year period, as was the absolute risk ratios for AF vs. no AF according to prior stroke and the number of additional risk factors. The study cohort comprised of 3 076 355 persons without AF and 48 189 with AF. For men aged 50 years, with no risk factors, the 5-year risk of stroke was 1.1% (95% confidence interval 1.1-1.1); with AF alone 2.5% (1.8-3.2); with one risk factor and no prior stroke or AF 2.5% (2.3-2.7); and with one factor, no prior stroke and AF 2.9% (1.4-4.3). In men aged 50 years with prior stroke as the only risk factor, 5-year risk was 10.2% (9.1-11.3). In men aged 70 years, the corresponding risks were 4.8% (4.7-4.9), 6.8% (5.7-7.9), 6.6% (6.3-6.8), 8.7 (7.4-9.9), and 19.1% (18.1-20.1), respectively. In women aged 50 years, the risk was of 0.7% (0.7-0.7), 2.1% (0.9-3.2), 1.6% (1.4-1.8), 4.1% (0.6-7.6), and 7.2% (6.3-8.2), respectively, and in women aged 70 years 3.4% (3.3-3.5), 8.2% (7.0-9.5), 4.6% (4.4-4.8), 9.1% (7.5-10.6), and 15.4% (14.5-16.4), respectively.
CONCLUSIONS: Stroke/TE/TIA risk was particularly increased when prior stroke/TE/TIA was present. Atrial fibrillation is associated with an increase in risk of stroke/TE/TIA in the absence of other risk factors but only a moderate increase in risk when other risk factors are present. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author 2016. For permissions please email: journals.permissions@oup.com.

Entities:  

Keywords:  Atrial fibrillation; Epidemiology; Risk factors; Stroke

Mesh:

Year:  2016        PMID: 26838693     DOI: 10.1093/europace/euv401

Source DB:  PubMed          Journal:  Europace        ISSN: 1099-5129            Impact factor:   5.214


  16 in total

1.  Management of Complications in Anticoagulated Patients with Atrial Fibrillation.

Authors:  George D Katritsis; Demosthenes G Katritsis
Journal:  Arrhythm Electrophysiol Rev       Date:  2017-12

2.  Left Atrial Volume as a Biomarker of Atrial Fibrillation at Routine Chest CT: Deep Learning Approach.

Authors:  Alex Bratt; Zachary Guenther; Lewis D Hahn; Michael Kadoch; Patrick L Adams; Ann N C Leung; Haiwei H Guo
Journal:  Radiol Cardiothorac Imaging       Date:  2019-12-19

3.  Impact of atrial fibrillation on the risk of ischemic stroke in patients on hemodialysis: BOREAS-HD3 Study.

Authors:  Ayumu Kimura; Marenao Tanaka; Norihito Moniwa; Arata Osanami; Koki Abe; Daisuke Miyamori; Yufu Gocho; Satoru Shibata; Makoto Terasawa; Yusuke Okazaki; Tomohisa Yamashita; Masayuki Koyama; Masato Furuhashi; Hirofumi Ohnishi; Tetsuji Miura
Journal:  Clin Exp Nephrol       Date:  2020-11-18       Impact factor: 2.801

Review 4.  Established and potential echocardiographic markers of embolism and their therapeutic implications in patients with ischemic stroke.

Authors:  Paulina E Gąsiorek; Maciej Banach; Marek Maciejewski; Andrzej Głąbiński; Aleksandra Paduszyńska; Jacek Rysz; Agata Bielecka-Dąbrowa
Journal:  Cardiol J       Date:  2018-05-02       Impact factor: 2.737

5.  Paroxysmal Atrial Fibrillation: An Independent Risk Factor for Prothrombotic Conditions.

Authors:  Mariya Negreva; Krasimira Prodanova; Ana Zarkova
Journal:  J Atr Fibrillation       Date:  2020-08-31

6.  Modelling tool to support decision-making in the NHS Health Check programme: workshops, systematic review and co-production with users.

Authors:  Martin O'Flaherty; Ffion Lloyd-Williams; Simon Capewell; Angela Boland; Michelle Maden; Brendan Collins; Piotr Bandosz; Lirije Hyseni; Chris Kypridemos
Journal:  Health Technol Assess       Date:  2021-05       Impact factor: 4.014

Review 7.  Relationship between hemoglobin A1c and serum troponin in patients with diabetes and cardiovascular events.

Authors:  Stjepan Šimić; Tomo Svaguša; Ingrid Prkačin; Tomislav Bulum
Journal:  J Diabetes Metab Disord       Date:  2019-11-11

8.  Sacubitril/Valsartan Decreases Atrial Fibrillation Susceptibility by Inhibiting Angiotensin II-Induced Atrial Fibrosis Through p-Smad2/3, p-JNK, and p-p38 Signaling Pathways.

Authors:  Song-Nan Li; Jing-Rui Zhang; Lu Zhou; Hui Xi; Chang-Yi Li; Lei Zhao
Journal:  J Cardiovasc Transl Res       Date:  2021-06-01       Impact factor: 4.132

9.  Atrial Fibrillation and Cause-Specific Risks of Pulmonary Embolism and Ischemic Stroke.

Authors:  Erin M Hald; Ludvig B Rinde; Maja-Lisa Løchen; Ellisiv B Mathiesen; Tom Wilsgaard; Inger Njølstad; Sigrid K Brækkan; John-Bjarne Hansen
Journal:  J Am Heart Assoc       Date:  2018-01-29       Impact factor: 5.501

10.  Genetic Interactions with Age, Sex, Body Mass Index, and Hypertension in Relation to Atrial Fibrillation: The AFGen Consortium.

Authors:  Lu-Chen Weng; Kathryn L Lunetta; Martina Müller-Nurasyid; Albert Vernon Smith; Sébastien Thériault; Peter E Weeke; John Barnard; Joshua C Bis; Leo-Pekka Lyytikäinen; Marcus E Kleber; Andreas Martinsson; Henry J Lin; Michiel Rienstra; Stella Trompet; Bouwe P Krijthe; Marcus Dörr; Derek Klarin; Daniel I Chasman; Moritz F Sinner; Melanie Waldenberger; Lenore J Launer; Tamara B Harris; Elsayed Z Soliman; Alvaro Alonso; Guillaume Paré; Pedro L Teixeira; Joshua C Denny; M Benjamin Shoemaker; David R Van Wagoner; Jonathan D Smith; Bruce M Psaty; Nona Sotoodehnia; Kent D Taylor; Mika Kähönen; Kjell Nikus; Graciela E Delgado; Olle Melander; Gunnar Engström; Jie Yao; Xiuqing Guo; Ingrid E Christophersen; Patrick T Ellinor; Bastiaan Geelhoed; Niek Verweij; Peter Macfarlane; Ian Ford; Jan Heeringa; Oscar H Franco; André G Uitterlinden; Uwe Völker; Alexander Teumer; Lynda M Rose; Stefan Kääb; Vilmundur Gudnason; Dan E Arking; David Conen; Dan M Roden; Mina K Chung; Susan R Heckbert; Emelia J Benjamin; Terho Lehtimäki; Winfried März; J Gustav Smith; Jerome I Rotter; Pim van der Harst; J Wouter Jukema; Bruno H Stricker; Stephan B Felix; Christine M Albert; Steven A Lubitz
Journal:  Sci Rep       Date:  2017-09-12       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.